Shop

The Houston Press finds that a prominent reproductive biologist at Baylor College of Medicine entered into a terminology transfer agreement with her employer and a private biotechnology company. Her "partners" then terminated the agreement, which, unbeknownst to the scientist, granted ownership of her life's work to the company. The company then used the scientist technology to take the company public and raise funds from investors, only to shelve the research and begin marketing a questionable treatment for male impotency. Allegations of fraudulent stock promotion have been made by investors.